

# ***NUVELLUS™ FOCAL CONTOURING SYSTEM***

**Tom Albright**

**CEO - Recros Medica**

**[talbright@recrosmedica.com](mailto:talbright@recrosmedica.com)**

May 2019



# Nuvellus™ Focal Contouring System



## Console:

Vacuum, Motor Control



## Motor and Handpiece:

Reusable, attaches to all consumables



Single Scalpet &  
Depth Guide



Multi-Scalpet  
Array (MSA)




Lipectomy  
Cannula

## Consumable Kit:

Single use, sterile package

**Capital equipment, reusable and per patient consumable revenue streams**



Rotating scalpets  
1.5 mm diameter

# Clinical Results Validated by CONFORM Study

- 68 subjects enrolled at 6 US sites
- Submental contouring procedure
  - Skin resection and focal lipectomy
  - **Single treatment**
  - **Results within 1 week**
- Endpoints include:
  - Quantitative image analysis
  - Patient satisfaction questionnaire
  - Unbiased review of photographs



Steven Dayan, MD  
Facial Plastic Surgeon,  
Chicago



Hema Sundaram, MD  
Dermatologist  
Fairfax VA



Jonathan Sykes, MD  
Facial Plastic Surgeon,  
Sacramento



Jill Waibel, MD  
Dermatologist,  
Miami




Steven Yoelin, MD  
Ophthalmologist,  
Newport Beach



Kamakshi Zeidler, MD  
Plastic Surgeon,  
San Jose

# Rapid & Clinically Significant Improvement


Moderate 2



\* See complete data presentation at ASAPS meeting on Monday, May 20<sup>th</sup> at 7:30 am

5-point scales (0-4); mild or moderate at baseline

# High Subject Satisfaction - Neck & Jawline Appearance




Subject-reported outcome; 6-point scale; \* $p < 0.0001$  compared to baseline



# 94% Likelihood to Recommend to Friends & Family

Likelihood to Recommend




- Extremely Likely
- Very Likely
- Somewhat Likely
- A Little Likely
- Not at all Likely



# Acceptable Safety Profile

- Very low procedure and recovery pain



- 80% of subjects had no visible scarring at Day 90
- Mild erythema (untreated in this protocol) is present in most subjects
- Low adverse event rate, no severe reports

# CONFORM Subject 101-002



Baseline

Day 7

Day 30

Day 90

Day 180

# U.S. Regulatory Pathway is Underway

---


- FDA Class II De Novo
  - Agreement with FDA
  - Pathway for innovative products with no predicate
  - 150 day review clock
- De Novo application submitted to FDA on 24Apr19
- FDA clearance expected in 4Q19

# Strong Intellectual Property

---

- 4 issued patents with exclusivity to 2034
- Over 60 US and International patent applications
- Numerous apparatus claims:
  - Key components of the medical devices
- Novel method claims:
  - Describe the procedure
  - Mechanisms of action (MOA)
    - Biological MOA
    - Biophysical MOA
- FTO – completed by K&L Gates

# Achievements & Plans



# Recros Medica Summary

---

- We expect Recros Medica to be a \$300M business with 80% gross margin within 5-years
- Nuvellus™ fulfills an untapped need in the large & growing skin laxity/contouring market
- We have clinical data, mature technology, defined FDA pathway and extensive IP
- We expect to achieve excellent outcomes for patients, physicians, and investors